Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis
暂无分享,去创建一个
J. Hoofnagle | T. Liang | D. Kleiner | R. Loomba | J. Feld | M. Ricks | A. Sumner | A. Modi | G. Lutchman | B. Borg | T. Liang | R. Loomba | J. Feld | P. Nagabhyru | J. Feld
[1] D. Kleiner,et al. Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[2] J. Hardies,et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.
[3] T. Harris,et al. Lipin 1 is an inducible amplifier of the hepatic PGC-1α/PPARα regulatory pathway , 2006 .
[4] M. Febbraio,et al. CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK , 2006, Nature Medicine.
[5] T. Harris,et al. Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. , 2006, Cell metabolism.
[6] S. Sanderson,et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.
[7] F. Anania,et al. The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. , 2005, The American journal of pathology.
[8] G. Marchesini,et al. A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease , 2005, The American Journal of Gastroenterology.
[9] R. Deutsch,et al. A phase 2 clinical trial of metformin as a treatment for non‐diabetic paediatric non‐alcoholic steatohepatitis , 2005, Alimentary pharmacology & therapeutics.
[10] J. Clore,et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[11] G. Farr,et al. Metformin in the treatment of non‐alcoholic steatohepatitis: a pilot open label trial , 2004, Alimentary pharmacology & therapeutics.
[12] L. Burgart,et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial , 2004, Hepatology.
[13] J. Hoofnagle,et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis , 2004, Hepatology.
[14] R. Turner,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.
[15] B. Neuschwander‐Tetri,et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐γ ligand rosiglitazone , 2003, Hepatology.
[16] H. Cortez‐Pinto,et al. Erratum: Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference (Hepatology (2003) 37 (1202-1219)) , 2003 .
[17] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.
[18] Peter J Moate,et al. MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. , 2003, Diabetes technology & therapeutics.
[19] S. Fowler,et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .
[20] J. P. Kay,et al. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. , 2001, Metabolism: clinical and experimental.
[21] S. Caldwell,et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis , 2001, American Journal of Gastroenterology.
[22] F. Kuhajda,et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice , 2000, Nature Medicine.
[23] S Fiorini,et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. , 2000, The Journal of clinical endocrinology and metabolism.
[24] Jay D. Horton,et al. Increased Levels of Nuclear SREBP-1c Associated with Fatty Livers in Two Mouse Models of Diabetes Mellitus* , 1999, The Journal of Biological Chemistry.
[25] Z. Younossi,et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.
[26] C. Day,et al. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. , 1998, Journal of hepatology.
[27] J. Ludwig,et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.